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Hyperglycemia that does not satisfy the diagnostic criteria for diabetes mellitus (DM) is generally called prediabetes (preDM). 
The global prevalence of preDM has been increasing progressively in the past few decades, and it has been established that preDM 
status is a strong risk factor for DM and cardiovascular disease. Currently, preDM status is classified into two subtypes: impaired 
fasting glucose and impaired glucose tolerance. Currently, preDM is not regarded as an independent clinical entity, but only as a 
risk factor for others. In this article, we review various clinical aspects of preDM in terms of the working definition, changes in 
criteria over the years, epidemiology, and pathophysiological characteristics, and its clinical significance in current medicine.
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INTRODUCTION
Non-diabetic hyperglycemia that does not satisfy the diagnos-
tic criteria for diabetes mellitus (DM) is generally known as 
prediabetes (preDM). It is generally agreed that all forms of 
diabetes pass through this prediabetic state before escalating 
into full-blown diabetes [1]. Similar to DM, fasting plasma 
glucose (FPG) and oral glucose tolerance tests are both used 
independently as defining criteria for preDM [1,2]. Recently, 
hemoglobin A1c (HbA1c) has also been used in the diagnosis 
of preDM [1,3].
  Because it is well-established that the risks of type 2 DM 
(T2DM) and cardiovascular disease are significantly increased 
in preDM subjects, life style modifications have been recom-
mended for this population as a method to control preDM 
[2,4]. The benefits of this have been confirmed in many pro-
spective, randomized studies where life style modification and 
pharmacological intervention have been shown to significant-
ly improve clinical markers related to the risk of T2DM and 
cardiovascular disease [5-7]. However, current preDM medi-
cal guidelines treat this condition as a risk factor for diabetes 
and cardiovascular disease, rather than a separate clinical enti-
ty. Additionally, the clinical significance of preDM has not been 
clearly established [1,2,4]. Studies suggest that preDM has spe-
cific clinical significance separate from type 2 diabetes. Because 
of this, it is thought that more active discussions are needed on 
the topic. Here, we review various clinical aspects of preDM 
with respect to the working definition, changes in criteria over 
time, epidemiology, pathophysiological characteristics, and its 
clinical significance in current medicine.
DEFINITION OF PREDIABETES AND 
DIAGNOSTIC CRITERIA 
According to the most recent clinical practice recommenda-
tions published in 2010 by the American Diabetes Association 
(ADA), preDM is defined as 1) impaired fasting glucose (IFG) 
with fasting plasma glucose levels of 100 to 125 mg/dL (5.6 to 
6.9 mmol/L), 2) impaired glucose tolerance (IGT) with plasma 
glucose levels of 140 to 199 mg/dL (7.8 to 11.0 mmol/L) 2-hour 
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postprandial, or 3) an HbA1c of 5.7 to 6.4% [1]. These criteria 
have evolved over the years and discussions on the topic con-
tinue.
Changes in preDM diagnostic criteria
In the 1979 American National Diabetes Data Group (NDDG) 
report, the first consensus-based, systematic criteria for DM 
were proposed. Specifically, non-diabetic hyperglycemia was 
defined as being in the high-risk group for the progression of 
DM and the presence of IGT [8]. The diagnostic criteria for 
IGT required satisfaction of the following three conditions: 1) 
FPG <140 mg/dL (7.8 mmol/L), 2) FPG ≥200 mg/dL (11.1 
mmol/L) 0.5, 1, and 1.5 hours after a 75-g oral glucose toler-
ance test, 3) and FPG between 140 and 200 mg/dL (7.8 to 11.1 
mmol/L) 2 hours after a 75-g oral glucose tolerance test [8]. 
However, the diagnostic criteria for IGT based on the NDDG 
reports are somewhat restricting, and there were difficulties 
including some subjects during the screening period [9].
  The diagnostic criteria for IGT that were published by the 
World Health Organization (WHO) in 1980 were simpler than 
the NDDG classification criteria. IGT was defined by a 2-hour 
plasma glucose level of 140 to 200 mg/dL (8.0 to 11.0 mmol/L) 
after a 75-g oral glucose tolerance test [10]. However, WHO 
criteria excluded the fasting criteria in the IGT diagnosis and 
only emphasized post-challenge glucose. This is because confir-
mation of fasting during screening is not easily obtained [10].
  Eighteen years after the NDDG report, ADA proposed new 
diagnosis criteria for DM in 1997 [11]. When considering the 
cost, time, and reproducibility of oral glucose tolerance tests, it 
was recommended that diabetes screening and diagnostic tests 
primarily use the FPG test. Based on macrovascular complica-
tion risks, the threshold for the diagnostic criterion changed 
from 140 to 126 mg/dL [11]. Thus, according to these criteria, 
a fasting glucose of 110 to 126 mg/dL in preDM (6.1 to 7.0 
mmol/L) is classified as IFG, while a 2-hour post-challenge 
plasma glucose concentration between 140 and 200 mg/dL 
(7.8 to 11.1 mmol/L) is now classified as IGT. The WHO diag-
nostic criteria that were released in 1999 were very similar to 
the ADA diagnostic criteria [12,13].
  To prevent similarity between IGT and IFG, in the ADA 
Expert Committee report, the IFG criteria was changed from 
110 mg/dL (6.1 mmol/L) to 100 mg/dL in 2003 (5.6 mmol/L) 
[14,15]. Recently, the International Expert Committee recom-
mended that HbA1c be added to the diagnosis of DM; the 2010 
ADA clinical practice recommendation defining HbA1c levels 
of over 6.5% as DM, and an HbA1c between 5.7 and 6.4% as 
preDM [1,3].
Major issues in diagnostic criteria changes for preDM
The diagnostic criteria for diabetes and preDM have been 
changed several times, and the use of A1c and others tests as 
diagnostic criteria for DM have been actively discussed. How-
ever, there does not appear to be a complete consensus regard-
ing this matter.
Issues regarding IFG criteria
To determine the cut-off values for preDM, criteria that sharp-
ly delineate increases in the risk of adverse clinical or metabol-
ic outcomes based on changes in blood glucose are needed. 
These questions are important for both IFG and IGT. However, 
unlike the widely accepted IGT criteria, controversy remains 
regarding diagnostic criteria for IFG.
  In 2003, the ADA recommended that the criterion for IFG 
be lowered from 110 mg/dL (6.1 mmol/L) to 100 mg/dL (5.6 
mmol/L) [14]. This change was based on receiver operating 
characteristic (ROC) analysis results for fasting blood glucose 
levels. Specifically, these criteria were able to maximize sensi-
tivity and specificity in detecting DM over a period of 5 years 
from Pima Indian, Mauritius, San Antonio, and Hoorn Study 
data [14,16-18]. The cut-off value for maximum sensitivity and 
specificity for detecting DM was set at 97 to 99 mg/dL (5.4 to 
5.5 mmol/L) [14]. Additionally, by lowering the IFG cut-off 
value, IFG prevalence became similar to IGT prevalence, and 
the percentages of people who were screened for FPG and 
postprandial blood glucose were similarly matched [14].
  However, the WHO advised that the cut-off value for IFG 
should be maintained at 110 mg/dL, because IFG prevalence 
would be increased significantly by changing the cut-off crite-
rion. Although this could have important personal or social 
impacts, there is not a major reduction in adverse outcomes or 
the prevention of DM progression as a result of this change [19].
  The actual risk of developing DM is known to be associated 
with an increase in FPG concentrations from “normal” condi-
tions. In studies conducted in young men, the risk of develop-
ing diabetes gradually increased when fasting blood glucose 
levels rose from under 81 mg/dL (4.5 mmol/L) to over 86 mg/
dL (4.8 mmol/L) [20]. This result suggests that there is no ex-
act cut-off value for FPG levels that predicts adverse outcomes. 
Additionally, in the Atherosclerosis Risk in Communities 
(ARIC) study, when FPG levels were over 106 mg/dL (5.9 109
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mmol/L), it was predicted with 50% sensitivity that subjects 
would develop diabetes, whereas when FPG was over 100 mg/
dL (5.6 mmol/L), it was predicted with 70% sensitivity; thus, 
higher-risk groups could be screened for. However, the per-
centage of the population that can be screened as a high-risk 
group increases by more than double the normal value with 
this kind of increase in sensitivity [21]. Additionally, when the 
ADA diagnostic criterion cut-off value was lowered, new IFG 
patients had more favorable cardiovascular risk profiles and a 
lower risk of developing diabetes compared with patients who 
were selected by the WHO criteria [22-25]. For these reasons, 
many diabetes experts did not completely agree with the ADA’s 
IFG diagnostic criteria [19,22,26].
HbA1c criteria issues
A1c had been widely used as a test to estimate the degree of 
glycemic control. Because it can be measured regardless of food 
intake, A1c is simpler than FPG or oral glucose tolerance tests. 
Additionally, because it reflects long-term glucose concentra-
tions, versus frequently changing glucose levels, it is more 
closely related to the chronic complications of diabetes [27-29]. 
Because the current DM diagnostic criteria are based on an 
increased risk of developing DM-related chronic complica-
tions, using A1c for the diagnosis of DM is a rational approach. 
However, the cost of A1c compared with simple glucose tests 
is high. Additionally, because measurement standards have not 
been established, its use as a diagnostic criterion for diabetes 
has been limited. Measurement methods are continuously im-
proving, and according to the efforts of professionals from the 
American National Glycohemoglobin Standardization Pro-
gram, European International Federation of Clinical Chemis-
try, Japanese Diabetes Society/Japanese Society of Clinical 
Chemistry, and other organizations for measurement standard-
ization, A1c is now actively being considered as a diagnostic 
criterion for diabetes [27,30,31].
  In several studies that have examined the diagnostic value 
of A1c, compared with FPG, A1c has been shown to have low-
er variability and higher specificity [32]. Based on several pop-
ulation-based studies, the A1c cut-off value has been set at 5.9 
to 6.2% for estimated diabetes diagnoses [33-36]. Specifically, 
in the National Health and Nutrition Examination Survey 
(NHANES) III, where the mean value of the A1c cut-off was 
set at over 6.5%, diabetes diagnoses had a 99.6% specificity and 
a 43 to 44% sensitivity [37]. Based on the results of these stud-
ies, the International Expert Committee proposed that the 
new standard A1c value for the diagnosis of DM be changed 
to above 6.5%. Since this time, the ADA has adopted it as a 
new official diagnostic criterion [1,3].
  For preDM, the International Expert Committee also de-
cided that A1c values between 6 and 6.5% are considered to be 
in the high-risk category for diabetes [3]. In an actual popula-
tion-based study, participants who had A1c levels between 6 
and 6.5% had a 10-fold increase in the occurrence of diabetes 
compared with participants with A1c levels below 6% [38,39]. 
However, over 5 years, participants with A1c levels of 5.5 to 
6.0% had cumulative occurrence percentages between 12 and 
25%, which was 3 to 8 times higher than the control group. 
Based on data from NHANES study subjects, the closest A1c 
level for current IFG and IGT criteria was 5.5 to 6.0%; howev-
er, in the linear regression analysis, a fasting glucose level of 
100 mg/dL corresponded with an A1c of 5.4%, and a fasting 
glucose level of 110 mg/dL corresponded with an A1c of 5.6% 
[1]. When the A1c cut-off value for preDM was set at 5.7%, 
sensitivity was 39 to 45% and specificity was 81 to 91% for IFG 
and IGT predictions [1]. Based on large-scale prospective 
studies, when the preDM cut-off value was set at 5.7%, the 
sensitivity was 66% and specificity was 88% for predicting the 
risk of DM risk over the next 6 years [36]. Consistent with 
these results, an HbA1c of 5.7 to 6.4% was presented by the 
ADA as a preDM criterion [1].
  However, based on the current criteria, diagnosis of subjects 
screened using the A1c 5.7 to 6.4% criterion are not complete-
ly consistent with IFG and IGT methods. With respect to the 
fasting blood glucose cut-off values proposed by the ADA, it is 
expected that that it will take some time until the aforemen-
tioned diagnostic criteria are widely accepted.
EPIDEMIOLOGY OF PREDM
According to several epidemiological studies, the worldwide 
prevalence of preDM exceeds that of true diabetes. The preva-
lence of preDM is expected to increase, and factors related to 
race, age, and various characteristics related to gender are 
known to exist.
Prevalence
According to the IDF Diabetes Atlas, currently, the number of 
cases of IGT (2010) worldwide is estimated to be approximate-
ly 340 million [40,41]. North America has the highest preva-
lence of IGT in the world, with 10.4%. For Europe and the Mid-110
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dle East, the values are 8.9% and 8.2%, respectively, which is 
also relatively high versus other parts of the world [41]. In 
Southeast Asia and the Western Pacific Region, the prevalenc-
es are 6.2% and 7.7%, respectively [41]. However, according to 
the absolute differences in population size, the Western Pacific 
Region is estimated to have the largest number of IGT subjects, 
approximately 120 million people [41]. When compared with 
DM, the prevalence of IGT is generally similar; however, in 
North America, the prevalence of IGT is lower than that of 
DM. In Africa and the Western Pacific Region, IGT prevalence 
is slightly higher than that of diabetes [41]. By 2030, the global 
prevalence of IGT is estimated to reach 8.4%, which will be 
approximately 462 million people [41].
  There are no additional comprehensive global estimates of 
IGF prevalence; however, in most parts of the world, it is known 
that the prevalence is above 5% [2]. In 2002, an IGT/IFG con-
sensus statement published by the International Diabetes Fed-
eration (IDF) stated that based on surveys conducted in many 
parts of the world, IGF prevalence was 2.0 to 17.3% [2]. Gen-
erally, the prevalence of IGT is known to be higher than that of 
IFG; however, these data were mostly based on the previous 
ADA/WHO criteria. According to the new ADA criteria, when 
the IFG cut-off value is adjusted to 100 mg/dL, IFG prevalence 
increases dramatically. In this case, the increase in IFG preva-
lence is greater than that of IGT [26,42]. For example, by 
changing the IFG diagnostic criteria, the Danish IFG preva-
lence increased from 11.8% to 37.6% [43]. Further, by chang-
ing the diagnostic criteria in DETECT-2 study subjects, IFG 
prevalence increased from 12.7% to 28.7% in Chinese subjects, 
from 11.0% to 38.6% in Asian Indians, from 16.3% to 45.7% in 
French subjects, and from 12.1% to 32.0% in the Unites States 
[44]. According to data from a survey on NHANES subjects, 
the IFG prevalence of Americans over the age of 20 was report-
ed as 25.7% and IGT was reported as 13.8% [45].
Overlap of IFG and IGT
The issue with the IFG and IGT concept began with whether 
screening for diabetic high-risk groups should be performed 
using fasting blood glucose or postprandial blood glucose tests. 
However, subjects selected through IFG and IGT criteria were 
not identical.
  Generally, among subjects screened using IGT, only 20 to 
25% of individuals have FPG levels ≥110 mg/dL. In subjects 
screened with IFG, <50% have a postprandial 2-hour glucose 
level ≥140 mg/dL [2]. In the DECODE studies, which exam-
ined European IFG subjects that were defined exclusively by 
FPG levels between 6.1 and 6.9 mmol/L, 64.8% of subjects had 
‘isolated’ IFG, 28.6% showed combined IFG with IGT, and 
6.6% were diagnosed with diabetes [2,46]. In the DECODA 
studies, 45.9% of Asian IFG subjects that were defined exclu-
sively by FPG levels had ‘isolated’ IFG, 35.2% showed IFG val-
ues that were associated with IGT, and 18.9% had diabetes [47]. 
Even in the analyses of NHANES subjects, only some of the 
preDM subjects showed overlap between IGT and IFG. Using 
the ADA IFG criteria, 60% of all IGT subjects were screened; 
however, among subjects classified as IFG, only 18.5% of IGT 
subjects could be screened.
  These data suggest that screening for all high-risk diabetes 
groups is not possible through the simple methods of either 
fasting glucose or postprandial blood glucose. Additionally, 
these results show that across physiological conditions, there 
can be a significant difference between IFG and IGT.
Characteristics of age and gender
Differences in age and gender between IFG and IGT are known 
to exist depending on the populations and region investigated. 
Generally, the prevalence of IFG and IGT increases according 
to age. Additionally, while IFG prevalence is relatively high in 
men, it is lower in women [2]. In the DECODE studies, the 
prevalence of isolated IFG in men increased gradually with 
age. In the 50 to 59 age group, IFG decreased gradually after 
reaching a plateau of 10.1%. Additionally, when the over 70 
group was excluded, prevalence in men was significantly high-
er [2,46,48]. The prevalence of isolated IGT increased continu-
ously regardless of gender, and excluding the over 70 group, 
the prevalence in women of all ages was significantly higher 
[2,46]. In the DECODA studies in Asians, excluding Indian 
cohorts, isolated IFG and isolated IGT prevalence both tended 
to increase with age, but not gender [2,47]. Differences by gen-
der were not significant when compared with Europeans. Fur-
ther, the isolated IFG prevalence of women in the same age 
group was much higher than in men, and women had higher 
incidences of isolated IGT [2,47]. Even in NHANES subjects, 
the prevalence of IFG and IGT increased proportionally with 
age [45]. However, IFG prevalence in men was 32.1%, com-
pared with 19.8% in women. There was no significant differ-
ence in IGT based on gender; IGT prevalence in men was 
14.6% and 13.1% in women [45]. There was also no observed 
difference in the prevalence of preDM in NHANES subjects 
based on ethnic backgrounds [45].111
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  There are differences between target populations in the above 
large-scale epidemiological survey results, and an exact com-
parison between each is very difficult. Estimating incidence is 
not possible using a cross-sectional design. Furthermore, with 
the rapidly changing lifestyle habits observed in many Asian 
countries, there is a problem applying epidemiological charac-
teristics longitudinally.
The clinical course of preDM
The risk for DM in preDM subjects is much higher compared 
with those with normal glucose tolerance (NGT). When sev-
eral prospective epidemiological studies were compiled, the 
incidence of T2DM in isolated IFG and IGT subjects was esti-
mated at 4 to 6% per year, and this value was significantly high-
er than NGT subjects (<0.5% per year) [5-7,13,16,49]. In the 
subjects who were diagnosed with IFG and IGT in combina-
tion, the annual percentage for the risk of developing T2DM 
increased by 10%. This suggests that IFG and IGT have addi-
tive roles in predicting the risk of developing T2DM. However, 
some preDM subjects also experienced complete recovery to 
normal glucose tolerance levels. In an 11-year follow-up study 
on Mauritius adults with IGT, 46% progressed into overt DM, 
28% retained their condition, 4% changed to IFG, and 24% 
showed normalized glucose tolerance [16]. For patients with 
IFG, 38% developed overt DM, 7% experienced no change, 
17% progressed to IGT, and 38% developed normalized glu-
cose tolerance [16].
  The occurrence of cardiovascular disease and associated 
mortality in preDM subjects compared with normal glucose 
tolerance are known to be significantly elevated [25,50,51]. In 
several studies, the risk of cardiovascular disease in preDM 
patients compared with NGT increased by over 50%, and this 
risk was greater in young adults [25]. However, in each study, 
there were differences in the risks of developing cardiovascu-
lar disease between IFG and IGT, and when confounding vari-
ables were compensated for, the risk of developing cardiovas-
cular disease was lowered [25]. As previously mentioned, in 
patients screened as having IFG based on the new ADA diag-
nostic criteria, and using the WHO criteria as a comparison, 
the cardiovascular risk profile is a little more favorable, and the 
risk of developing diabetes is known to be lower. There is much 
room for debate regarding IFG diagnostic criteria and the risk 
of developing cardiovascular disease [22-25].
PATHOPHYSIOLOGY OF PREDM
Epidemiological studies examining a large number of subjects 
who were independently screened for both IFG and IGT sug-
gest that the pathophysiological characteristics of IFG and IGT 
are significantly different [2]. The most important factors that 
may explain the pathophysiology of T2DM are increased insu-
lin resistance and decreased insulin secretion. Studies analyz-
ing insulin resistance and insulin secretion in isolated IFG and 
IGT subjects suggest that there are distinguishable character-
istics between the subtypes [52-57]. However, differences in 
pathophysiology between each preDM subtypes still do not 
clarify whether these commonly shared phenomena occur in 
various regions or ethnicities around the world. Additionally, 
their significance in clinical practice is unknown.
Perspectives on insulin resistance
During glucose stimulation, pancreatic insulin secretion phys-
iologically suppresses hepatic glucose production in the liver; 
however, glucose utilization is promoted in the peripheral tis-
sues, including muscle and adipose tissue. Insulin resistance 
refers to a dysfunctional physiological response to insulin se-
cretion in vivo. Despite normal or higher insulin levels, hepatic 
glucose production is not adequately suppressed, or a reduc-
tion in glucose utilization in peripheral tissue causes increased 
plasma glucose concentrations. Compared with NGT subjects, 
there is a significantly higher tendency for insulin resistance to 
increase in preDM subjects. Additionally, important differenc-
es in the mechanisms underlying insulin resistance are known 
to exist between preDM subtypes [42,52-55,57]. 
  Hepatic insulin resistance in IFG subjects is significantly 
higher than in NGT subjects. In contrast, peripheral insulin 
resistance is known to be significantly higher in IGT subjects 
[42,52,53,57]. Fasting blood glucose levels are significantly 
higher in basal hepatic glucose production in response to in-
sulin in IFG subjects, despite hyperinsulinemia, compared with 
NGT subjects. These results suggest that proper suppression 
does not occur; however, hepatic insulin resistance eventually 
increases in IFG subjects [42,52,57]. In IGT subjects, hepatic 
insulin resistance is significantly lower than in IFG subjects; 
however, there is no significant difference compared with NGT 
[42,52,57]. In studies that use the euglycemic hyperinsulinemic 
clamp, the gold-standard for assessing insulin resistance, total 
body glucose disposal in isolated IGT subjects is significantly 
reduced compared with NGT, while in isolated IFG, it is simi-112
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lar to NGT [58,59]. In isolated IGT subjects, this significantly 
increases insulin resistance in peripheral tissues. In contrast, 
peripheral insulin resistance is not significantly different be-
tween isolated IFG and NGT. While IFG is associated with 
IGT, both hepatic and peripheral insulin resistance are signifi-
cantly higher than NGT [42,52,55,57].
Perspectives on insulin secretion
The progressive failure of beta cells is the major factor under-
lying the development and progression of T2DM. Physiologi-
cal pancreatic insulin secretion occurs biphasically. Generally, 
sharply increasing early phase secretion and late phase secre-
tion can be divided by post-continuous glucose stimulation 
during initial glucose loading. Even if the same amount of glu-
cose is loaded, differences in in vivo insulin secretion exist 
during the course of administration. When glucose is admin-
istered orally, insulin secretion promotion occurs via the addi-
tional effects of incretin; however, when glucose is delivered 
intravenously, this effect is not observed [55]. It is well-known 
that a reduction in insulin secretion due to beta cell failure is 
an early step in NGT and preDM stages. In addition to simple 
reduction in insulin secretion, however, differences in beta cell 
dysfunction patterns are known to exist between preDM sub-
types [56,57,60].
  According to studies based on oral glucose tolerance tests, 
early phase insulin secretion in IFG subjects is significantly re-
duced compared with NGT, while late-phase insulin secretion 
is normal. Further, supranormal conditions can be observed 
[52,57]. On the other hand, early phase insulin secretion was 
relatively intact in IGT subjects, while late-phase insulin secre-
tion was severely decreased [52,57]. In other studies, first- and 
second-phase insulin secretion in IGT subjects decreased in 
response to glucose infusion, while in IFG subjects, first-phase 
secretion decreased and second-phase insulin secretion re-
mained relatively intact [54,55]. For both oral and intravenous 
glucose loads, symptoms of insulin secretion disorders in 
preDM subjects do not appear to be the result of incretin, but, 
instead, are caused by direct beta cell dysfunction. When IFG 
is accompanied by IGT, both early and late-phase insulin se-
cretion were extremely reduced [52,57].
Racial differences in the pathophysiological characteristics 
of preDM
Based on the results discussed above, it seems clear that there 
is a difference between insulin resistance and insulin secretion 
between IFG and IGT subjects; however, most studies have 
targeted Caucasians, and there are not many studies that in-
clude physiological characteristics of other races, including 
Asians.
  Using a 75-g oral glucose tolerance test, differences between 
insulin secretion and insulin resistance have recently been 
compared according to preDM subtypes in 307 Korean sub-
jects diagnosed with drug-naïve preDM [56]. 75-g oral glu-
cose tolerance test results were classified according to ADA di-
agnostic criteria: 87 subjects had isolated IFG, 75 had isolated 
IGT, and 145 had both. Within the subjects, homeostasis mod-
el assessment of insulin resistance (HOMA-IR) represents he-
patic insulin resistance, whole body insulin sensitivity index 
(WBISI; Matsuda index) represents peripheral insulin resis-
tance, the insulinogenic index (IGI) represents early phase in-
sulin secretion, AUC I/G0-120 represents late-phase insulin se-
cretion, and insulin resistance effects are compensated for. To 
assess beta cell function, the disposition index (DI, IGI× 
WBISI), was measured [56]. After adjusting for confounding 
variables, it was found that HOMA-IR, IGI, AUC I/G0–120, and 
DI were high in isolated IFG subjects, while only WBISI was 
high in isolated IGT subjects (Fig. 1) [56]. Although the gold-
standard was being used in this study, preDM pathophysiolo-
gy increased insulin resistance in IFG and reduced insulin se-
cretion in IGT. Additionally, there was an apparent difference 
among study results, which suggests that something else is 
playing a relatively important role [56]. In future, additional 
studies are required between each preDM subtype to determine 
the physiological characteristics in various regions around the 
world to confirm the most common racial characteristics.
Do pathophysiological characteristics between preDM 
subtypes have clinical significance?
It remains unclear as to how clinically important heterogeneous 
pathophysiological features are between the observed subtypes. 
In many of the previous prospective, randomized trials that 
used interventions such as lifestyle modification and pharma-
cological agents, the risk of developing T2DM decreased in 
preDM subjects and it is known that several cardiovascular 
risk factors can be significantly improved upon [5-7]. In previ-
ous studies, however, interventions according to preDM sub-
types have considered distinct pathophysiological characteris-
tics, which could not be tested in subjects. Although it is only 
a hypothesis, it is suspected that when medical interventions 
are made during preDM and the early phase of T2DM accord-113
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ing to hepatic/peripheral insulin resistance-dominant pheno-
type recognition or beta cell dysfunction-dominant phenotype 
recognition, more positive clinical outcomes may be obtained. 
For example, metformin and TZDs are used as insulin sensi-
tizers for hepatic/peripheral insulin resistance phenotypes. In 
contrast, for beta cell dysfunction phenotypes, GLP-1 antago-
nists are thought to be effective. Additional studies will be 
necessary to determine whether this hypothesis is accurate.
CONCLUSIONS
PreDM is an obvious risk factor for both T2DM and cardio-
vascular disease. However, there are almost no symptoms of 
preDM and the clinical course is variable. Because there is not 
a worldwide consensus on diagnostic criteria, there are inade-
quacies in defining it as a single disease. However, we feel that 
the prevalence of preDM is higher than that of T2DM, and 
there are many epidemiological characteristics involved in dif-
ferent regions and races. Compared with observable symp-
toms, physiologically dynamic changes are occurring. Through 
proper management, recovery of normal glucose tolerance is 
possible. Additionally, because complications can be prevent-
ed, the clinical approach is more aggressive and more time is 
required to develop a more systematic approach. This suggests 
that individual management is required given the observed 
significant pathophysiological heterogeneity between preDM 
subtypes for the management of preDM subjects. Through fu-
ture research, the pathophysiology of preDM and early stage 
T2DM is expected to become much more widely understood.
ACKNOWLEDGMENT
This article was supported by a grant from the Korea Health 
21 R&D Project, Ministry of Health and Welfare, Republic of 
Korea (Grant No. A050463).
REFERENCES
1. American Diabetes Association. Diagnosis and classification 
of diabetes mellitus. Diabetes Care 2010;33 Suppl 1:S62-9. 
  Isolated  Isolated
  IFG  IGT
3.0
2.5
2.0
1.5
1.0
0.5
0.0
H
O
M
A
-
I
R
a
  Isolated  Isolated
  IFG  IGT
6
5
4
3
2
1
0
W
B
I
S
I
a
  Isolated  Isolated
  IFG  IGT
6
5
4
3
2
1
0
D
i
s
p
o
s
i
t
i
o
n
 
i
n
d
e
x
 
(
I
G
I
×
W
B
I
S
I
)
a
  Isolated  Isolated
  IFG  IGT
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
I
G
I
b
  Isolated  Isolated
  IFG  IGT
0.6
0.4
0.2
0.0
A
U
C
 
I
/
G
0
-
1
2
0
b
Fig. 1. Comparison of insulin resistance and secretory indices between Korean prediabetic subjects after adjusting for age, gen-
der, body mass index, and abdominal circumference [56]. Data are presented as mean±standard error. HOMA-IR, homeostasis 
model assessment of insulin resistance; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; WBISI, whole body in-
sulin sensitivity index; IGI, insulinogenic index. 
aP<0.05, 
bP<0.01.114
Rhee SY, et al.
Diabetes Metab J 2011;35:107-116 http://e-dmj.org
2. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tol-
erance and impaired fasting glycaemia: the current status on 
definition and intervention. Diabet Med 2002;19:708-23. 
3. International Expert Committee. International Expert Com-
mittee report on the role of the A1C assay in the diagnosis of 
diabetes. Diabetes Care 2009;32:1327-34. 
4. American Diabetes Association. Standards of medical care in 
diabetes--2010. Diabetes Care 2010;33 Suppl 1:S11-61. 
5. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen 
H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, 
Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish 
Diabetes Prevention Study Group. Prevention of type 2 diabe-
tes mellitus by changes in lifestyle among subjects with im-
paired glucose tolerance. N Engl J Med 2001;344:1343-50. 
6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, 
Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Pro-
gram Research Group. Reduction in the incidence of type 2 di-
abetes with lifestyle intervention or metformin. N Engl J Med 
2002;346:393-403. 
7. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, 
Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, 
Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet 
and exercise in preventing NIDDM in people with impaired 
glucose tolerance. The Da Qing IGT and Diabetes Study. Dia-
betes Care 1997;20:537-44. 
8. National Diabetes Data Group. Classification and diagnosis of 
diabetes mellitus and other categories of glucose intolerance. 
Diabetes 1979;28:1039-57. 
9. Massari V, Eschwege E, Valleron AJ. Imprecision of new crite-
ria for the oral glucose tolerance test. Diabetologia 1983;24: 
100-6. 
10. Alberti KG, Zimmet PZ. Definition, diagnosis and classifica-
tion of diabetes mellitus and its complications. Part 1: diagno-
sis and classification of diabetes mellitus provisional report of 
a WHO consultation. Diabet Med 1998;15:539-53. 
11. Report of the Expert Committee on the Diagnosis and Classi-
fication of Diabetes Mellitus. Diabetes Care 1997;20:1183-97. 
12. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnos-
tic criteria for diabetes mellitus and other categories of glucose 
intolerance: 1997 criteria by the Expert Committee on the Di-
agnosis and Classification of Diabetes Mellitus (ADA), 1998 
WHO consultation criteria, and 1985 WHO criteria. World 
Health Organization. Diabetes Res Clin Pract 1999;44:21-6. 
13. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, 
Bennett PH, Knowler WC. The 1997 American Diabetes As-
sociation and 1999 World Health Organization criteria for hy-
perglycemia in the diagnosis and prediction of diabetes. Dia-
betes Care 2000;23:1108-12. 
14. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, 
Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan 
D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tu-
omilehto J, Zimmet P; Expert Committee on the Diagnosis 
and Classification of Diabetes Mellitus. Follow-up report on 
the diagnosis of diabetes mellitus. Diabetes Care 2003;26: 
3160-7. 
15. Expert Committee on the Diagnosis and Classification of Dia-
betes Mellitus. Report of the Expert Committee on the Diag-
nosis and Classification of Diabetes Mellitus. Diabetes Care 
2003;26 Suppl 1:S5-20. 
16. Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Chitson P, 
Gareeboo H, Hemraj F, Fareed D, Tuomilehto J, Alberti KG. 
Impaired fasting glucose or impaired glucose tolerance. What 
best predicts future diabetes in Mauritius? Diabetes Care 1999; 
22:399-402. 
17. Hanley AJ, Williams K, Gonzalez C, D’Agostino RB Jr, Wagen-
knecht LE, Stern MP, Haffner SM; San Antonio Heart Study; 
Mexico City Diabetes Study; Insulin Resistance Atherosclero-
sis Study. Prediction of type 2 diabetes using simple measures 
of insulin resistance: combined results from the San Antonio 
Heart Study, the Mexico City Diabetes Study, and the Insulin 
Resistance Atherosclerosis Study. Diabetes 2003;52:463-9. 
18. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Ste-
houwer CD, Nijpels G, Bouter LM, Heine RJ. Relation of im-
paired fasting and postload glucose with incident type 2 diabe-
tes in a Dutch population: The Hoorn Study. JAMA 2001;285: 
2109-13. 
19. World Health Organization. Definition and diagnosis of dia-
betes mellitus and intermediate hyperglycemia: report of a 
WHO/IDF consultation. Geneva: World Health Organization; 
2006.
20. Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat 
T, Kochba I, Rudich A; Israeli Diabetes Research Group. Nor-
mal fasting plasma glucose levels and type 2 diabetes in young 
men. N Engl J Med 2005;353:1454-62.
21. Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, 
Golden SH, Folsom AR, Chambless LE; Atherosclerosis Risk 
in Communities Investigators. Identifying individuals at high 
risk for diabetes: The Atherosclerosis Risk in Communities 
study. Diabetes Care 2005;28:2013-8. 
22. Forouhi NG, Balkau B, Borch-Johnsen K, Dekker J, Glumer C, 115
The prediabetic period: review of clinical aspects
Diabetes Metab J 2011;35:107-116 http://e-dmj.org
Qiao Q, Spijkerman A, Stolk R, Tabac A, Wareham NJ; EDEG. 
The threshold for diagnosing impaired fasting glucose: a posi-
tion statement by the European Diabetes Epidemiology Group. 
Diabetologia 2006;49:822-7. 
23. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglyce-
mia a risk factor for cardiovascular disease? A meta-analysis of 
prospective studies. Arch Intern Med 2004;164:2147-55. 
24. DECODE Study Group, European Diabetes Epidemiology 
Group. Is the current definition for diabetes relevant to mor-
tality risk from all causes and cardiovascular and noncardio-
vascular diseases? Diabetes Care 2003;26:688-96. 
25. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovas-
cular disease: a systematic review of the evidence. J Am Coll 
Cardiol 2010;55:1310-7. 
26. Davidson MB, Landsman PB, Alexander CM. Lowering the 
criterion for impaired fasting glucose will not provide clinical 
benefit. Diabetes Care 2003;26:3329-30. 
27. Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman 
D, Davidson MB. A new look at screening and diagnosing dia-
betes mellitus. J Clin Endocrinol Metab 2008;93:2447-53. 
28. Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, 
Klein R, Klein BE, Zimmet P, Shaw J. Relation between fasting 
glucose and retinopathy for diagnosis of diabetes: three popu-
lation-based cross-sectional studies. Lancet 2008;371:736-43. 
29. Sabanayagam C, Liew G, Tai ES, Shankar A, Lim SC, Subra-
maniam T, Wong TY. Relationship between glycated haemo-
globin and microvascular complications: is there a natural cut-
off point for the diagnosis of diabetes? Diabetologia 2009;52: 
1279-89. 
30. Weykamp C, John WG, Mosca A, Hoshino T, Little R, Jepps-
son JO, Goodall I, Miedema K, Myers G, Reinauer H, Sacks 
DB, Slingerland R, Siebelder C. The IFCC Reference Measure-
ment System for HbA1c: a 6-year progress report. Clin Chem 
2008;54:240-8. 
31. Tominaga M, Makino H, Yoshino G, Kuwa K, Takei I, Aono Y, 
Hoshino T, Umemoto M, Shimatsu A, Sanke T, Kuwashima M, 
Taminato T, Ono J. Japanese standard reference material for 
JDS Lot 2 haemoglobin A1c. I: comparison of Japan Diabetes 
Society-assigned values to those obtained by the Japanese and 
USA domestic standardization programmes and by the Inter-
national Federation of Clinical Chemistry reference laborato-
ries. Ann Clin Biochem 2005;42(Pt 1):41-6.
32. Bennett CM, Guo M, Dharmage SC. HbA(1c) as a screening 
tool for detection of type 2 diabetes: a systematic review. Dia-
bet Med 2007;24:333-43. 
33. Nakagami T, Tominaga M, Nishimura R, Yoshiike N, Daimon 
M, Oizumi T, Tajima N. Is the measurement of glycated hemo-
globin A1c alone an efficient screening test for undiagnosed 
diabetes? Japan National Diabetes Survey. Diabetes Res Clin 
Pract 2007;76:251-6. 
34. Herman WH, Engelgau MM, Zhang Y, Brown MB. Use of 
GHb (HbA(1c)) to screen for undiagnosed diabetes in the US 
population. Diabetes Care 2000;23:1207-8. 
35. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill 
A, Goldstein DE. Defining the relationship between plasma 
glucose and HbA(1c): analysis of glucose profiles and HbA(1c) 
in the Diabetes Control and Complications Trial. Diabetes 
Care 2002;25:275-8. 
36. Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Charles 
MA, Eschwege E; DESIR Study Group. Use of HbA1c in pre-
dicting progression to diabetes in French men and women: 
data from an Epidemiological Study on the Insulin Resistance 
Syndrome (DESIR). Diabetes Care 2006;29:1619-25. 
37. Buell C, Kermah D, Davidson MB. Utility of A1C for diabetes 
screening in the 1999 2004 NHANES population. Diabetes 
Care 2007;30:2233-5. 
38. Pradhan AD, Rifai N, Buring JE, Ridker PM. Hemoglobin A1c 
predicts diabetes but not cardiovascular disease in nondiabetic 
women. Am J Med 2007;120:720-7. 
39. Sato KK, Hayashi T, Harita N, Yoneda T, Nakamura Y, Endo G, 
Kambe H. Combined measurement of fasting plasma glucose 
and A1C is effective for the prediction of type 2 diabetes: the 
Kansai Healthcare Study. Diabetes Care 2009;32:644-6. 
40. Unwin N, Gan D, Whiting D. The IDF Diabetes Atlas: provid-
ing evidence, raising awareness and promoting action. Diabe-
tes Res Clin Pract 2010;87:2-3. 
41. International Diabetes Federation (IDF). IDF diabetes atlas. 
4th ed. Brussels: IDF Executive Office; 2010. 
42. Abdul-Ghani MA, DeFronzo RA. Pathophysiology of predia-
betes. Curr Diab Rep 2009;9:193-9. 
43. Glumer C, Jorgensen T, Borch-Johnsen K; Inter99 study. Prev-
alences of diabetes and impaired glucose regulation in a Dan-
ish population: the Inter99 study. Diabetes Care 2003;26:2335-
40. 
44. Borch-Johnsen K, Colagiuri S, Balkau B, Glumer C, Carstensen 
B, Ramachandran A, Dong Y, Gao W. Creating a pandemic of 
prediabetes: the proposed new diagnostic criteria for impaired 
fasting glycaemia. Diabetologia 2004;47:1396-402.
45. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li 
C, Williams DE, Gregg EW, Bainbridge KE, Saydah SH, Geiss 116
Rhee SY, et al.
Diabetes Metab J 2011;35:107-116 http://e-dmj.org
LS. Full accounting of diabetes and pre-diabetes in the U.S. 
population in 1988-1994 and 2005-2006. Diabetes Care 2009; 
32:287-94. 
46. DECODE Study Group on behalf of the European Diabetes 
Epidemiology Study Group. Will new diagnostic criteria for 
diabetes mellitus change phenotype of patients with diabetes? 
Reanalysis of European epidemiological data. BMJ 1998;317: 
371-5. 
47. Qiao Q, Hu G, Tuomilehto J, Nakagami T, Balkau B, Borch-
Johnsen K, Ramachandran A, Mohan V, Iyer SR, Tominaga M, 
Kiyohara Y, Kato I, Okubo K, Nagai M, Shibazaki S, Yang Z, 
Tong Z, Fan Q, Wang B, Chew SK, Tan BY, Heng D, Emmanu-
el S, Tajima N, Iwamoto Y, Snehalatha C, Vijay V, Kapur A, 
Dong Y, Nan H, Gao W, Shi H, Fu F; DECODA Study Group. 
Age- and sex-specific prevalence of diabetes and impaired glu-
cose regulation in 11 Asian cohorts. Diabetes Care 2003;26: 
1770-80. 
48. The DECODE study group, European Diabetes Epidemiology 
Group, Diabetes Epidemiology: Collaborative analysis Of Di-
agnostic criteria in Europe. Glucose tolerance and mortality: 
comparison of WHO and American Diabetes Association di-
agnostic criteria. Lancet 1999;354:617-21. 
49. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, 
Heine RJ. The 1997 American Diabetes Association criteria 
versus the 1985 World Health Organization criteria for the di-
agnosis of abnormal glucose tolerance: poor agreement in the 
Hoorn Study. Diabetes Care 1998;21:1686-90. 
50. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship 
between glucose and incident cardiovascular events. A metare-
gression analysis of published data from 20 studies of 95,783 
individuals followed for 12.4 years. Diabetes Care 1999;22: 
233-40. 
51. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. 
Postchallenge hyperglycemia and mortality in a national sam-
ple of U.S. adults. Diabetes Care 2001;24:1397-402. 
52. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, 
DeFronzo RA. Insulin secretion and action in subjects with 
impaired fasting glucose and impaired glucose tolerance: re-
sults from the Veterans Administration Genetic Epidemiology 
Study. Diabetes 2006;55:1430-5. 
53. Meyer C, Pimenta W, Woerle HJ, Van Haeften T, Szoke E, Mi-
trakou A, Gerich J. Different mechanisms for impaired fasting 
glucose and impaired postprandial glucose tolerance in hu-
mans. Diabetes Care 2006;29:1909-14. 
54. Perreault L, Bergman BC, Playdon MC, Dalla Man C, Cobelli 
C, Eckel RH. Impaired fasting glucose with or without im-
paired glucose tolerance: progressive or parallel states of predi-
abetes? Am J Physiol Endocrinol Metab 2008;295:E428-35. 
55. Faerch K, Vaag A, Holst JJ, Glumer C, Pedersen O, Borch-
Johnsen K. Impaired fasting glycaemia vs impaired glucose 
tolerance: similar impairment of pancreatic alpha and beta cell 
function but differential roles of incretin hormones and insu-
lin action. Diabetologia 2008;51:853-61. 
56. Rhee SY, Woo JT, Chon S, Hwang YC, Oh S, Ahn KJ, Chung 
HY, Kim SW, Kim JW, Kim YS. Characteristics of insulin resis-
tance and insulin secretory capacity in Korean subjects with 
IFG and IGT. Diabetes Res Clin Pract 2010;89:250-5. 
57. Faerch K, Vaag A, Holst JJ, Hansen T, Jorgensen T, Borch-
Johnsen K. Natural history of insulin sensitivity and insulin 
secretion in the progression from normal glucose tolerance to 
impaired fasting glycemia and impaired glucose tolerance: the 
Inter99 study. Diabetes Care 2009;32:439-44. 
58. Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of 
individuals with impaired fasting glucose and/or impaired 
glucose tolerance. Diabetes 1999;48:2197-203. 
59. Wasada T, Kuroki H, Katsumori K, Arii H, Sato A, Aoki K. 
Who are more insulin resistant, people with IFG or people 
with IGT? Diabetologia 2004;47:758-9. 
60. Rhee SY, Kim JY, Chon S, Hwang YC, Jeong IK, Oh S, Ahn KJ, 
Chung HY, Woo J, Kim SW, Kim JW, Kim YS. The changes in 
early phase insulin secretion in newly diagnosed, drug naïve 
Korean prediabetes subjects. Korean Diabetes J 2010;34:157-
65. 